AMY RUSSELL: Open Payments
NPI 1184396640 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 24 payments from 8 companies in 2025. Trend: 2023 $181 · 2024 $311 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 2 | $221 |
| Ardelyx, Inc. | 6 | $199 |
| Merck Sharp & Dohme LLC | 4 | $103 |
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| GENZYME CORPORATION | 1 | $91 |
| Novo Nordisk Inc | 3 | $87 |
| Boston Scientific Corporation | 3 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $42 |
Products named: XPHOZAH 30 MG, Empaveli, LEQVIO, Wegovy, IBSRELA, VERQUVO, XIFAXAN, WATCHMAN Access System.
Industry payments across VA — which companies pay providers there.
